

**Selective and Immunomodulating Effect Of The Anticancer Preparation NSC-631570 (Ukrain)**

Wassil Nowicky

Nowicky Pharma / Ukrainian Anti-Cancer Institute, Vienna, Austria University

Keywords: oncology, anticancer, NSC-631570, Ukrain, proton

Abstract:

Researchers from Eberhard-Karls-University Tübingen, Germany, investigated the effects of NSC-631570 on cell survival, alteration of the cell cycle and induction of apoptosis without and in combination with ionising radiation (IR) at a dose of 1-10 Gy. The tests were performed on the exponentially growing human tumor cells MDA-MB-231 (breast), PA-TU-8902 (pancreas), CCL-221 (colon cancer), U-138MG (glioblastoma), and human skin and lung fibroblasts HSF1, HSF2 and CCD32-LU. Without IR, NSC-631570 exerted a time- and dose-dependant cytotoxic effect, more pronounced against the cancer cells. Flow cytometry revealed NSC-631570 to modulate radiation toxicity against human cancer cell lines and to protect normal cells from radiation. The combination of NSC-631570 plus IR gave enhanced toxicity in CCL-221 and U-138MG cells with their accumulation in the G2/M phase of the cell cycle, but not in MDA-MB-231 and PA-TU-8902 cells. A radio protective effect was found in normal human skin and lung fibroblasts. The authors suggest a reasonable use of NSC-631570 in combined radiochemotherapy [1]. The cytotoxic effects of NSC-631570 were evaluated in two primary pancreatic cancer cell lines (PPTCC), fibroblasts derived from pancreatic ductal adenocarcinoma specimens (F-PDAC), and an immortalized epithelial ductal pancreatic cell line (HPNE). Cytotoxicity was assessed by the CellTiter 96 kit based on the cellular metabolism of the tetrazolium compound XTT, which is reduced by living cells to yield a soluble formazan product in the presence of the electron coupling agent phenazine methosulfate, while the modulation of NSC-631570 uptake in the medium was studied using the fluorescence of NSC-631570 with the AlphaDigiDoc software by UV and HPNE cells. These data demonstrated the selective effect of Ukrain in PPTCCs, which may be related to a different transport system or higher metabolism of the drug in PDAC, and warrant further investigations in order to support the possible role of Ukrain in PDAC treatment [2].

**Biography:**

Dr. Wassil Nowicky – Dipl. Ing., Dr. techn., DDDr. h. c., Director of “Nowicky Pharma” and President of the Ukrainian Anti-Cancer Institute (Vienna, Austria). He has finished his study at the Radiotechnical Faculty of the Technical University of Lviv (Ukraine) at the end of 1955 with graduation to “Diplomingenieur” in 1960 which title was nostrificated in Austria in 1975. Inventor of the anticancer preparation on basis of celandine alkaloids “NSC-631570”. Author of over 300 scientific articles dedicated to cancer research. Dr. Wassil Nowicky is a real member of the New York Academy of Sciences, member of the European Union for applied immunology and of the American Association for scientific progress, honorary doctor of the Janka Kupala University in Hrodno, doctor “honoris causa” of the open international university on complex medicine in Colombo, honorary member of the Austrian Society of a name of Albert Schweizer. He has received the award for merits of National guild of pharmacists of Americ, the award of Austrian Society of sanitary, hygiene and public health services and others.